Alembic Limited (ALEMBICLTD.NS)
INR 103.77
(5.99%)
INR 103.77
(5.99%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.57 Billion INR | 23.77% |
| 2022 | 1.27 Billion INR | 78.28% |
| 2021 | 713.69 Million INR | 5.21% |
| 2020 | 678.37 Million INR | 0.87% |
| 2019 | 672.55 Million INR | -42.46% |
| 2018 | 1.16 Billion INR | -2.18% |
| 2017 | 1.19 Billion INR | -11.21% |
| 2016 | 1.34 Billion INR | 6.78% |
| 2015 | 1.26 Billion INR | -12.68% |
| 2014 | 1.44 Billion INR | -6.04% |
| 2013 | 1.53 Billion INR | -14.29% |
| 2012 | 1.79 Billion INR | -87.78% |
| 2011 | 14.66 Billion INR | 630.33% |
| 2010 | 2 Billion INR | -82.36% |
| 2009 | 11.38 Billion INR | 1.98% |
| 2008 | 11.16 Billion INR | 8.71% |
| 2007 | 10.26 Billion INR | 42.22% |
| 2006 | 7.21 Billion INR | 12.99% |
| 2005 | 6.38 Billion INR | 21.81% |
| 2004 | 5.24 Billion INR | -5.75% |
| 2003 | 5.56 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 507.8 Million INR | 3.55% |
| 2023 Q1 | 368.4 Million INR | -0.73% |
| 2023 FY | 1.57 Billion INR | 23.77% |
| 2023 Q2 | 322.8 Million INR | -12.38% |
| 2023 Q3 | 393.2 Million INR | 21.81% |
| 2023 Q4 | 490.4 Million INR | 24.72% |
| 2022 Q4 | 371.1 Million INR | 21.23% |
| 2022 Q1 | 220.9 Million INR | 93.95% |
| 2022 Q2 | 374.2 Million INR | 69.4% |
| 2022 Q3 | 306.1 Million INR | -18.2% |
| 2022 FY | 1.27 Billion INR | 78.28% |
| 2021 FY | 713.69 Million INR | 5.21% |
| 2021 Q4 | 113.89 Million INR | -40.53% |
| 2021 Q3 | 191.5 Million INR | -1.85% |
| 2021 Q2 | 195.1 Million INR | -6.29% |
| 2021 Q1 | 208.2 Million INR | -10.29% |
| 2020 Q2 | 167.6 Million INR | 25.17% |
| 2020 Q3 | 144.8 Million INR | -13.6% |
| 2020 FY | 678.37 Million INR | 0.87% |
| 2020 Q4 | 232.07 Million INR | 60.27% |
| 2020 Q1 | 133.9 Million INR | 178.09% |
| 2019 Q3 | 127.6 Million INR | -46.05% |
| 2019 Q2 | 236.5 Million INR | -9.14% |
| 2019 Q4 | 48.15 Million INR | -62.26% |
| 2019 FY | 672.55 Million INR | -42.46% |
| 2019 Q1 | 260.3 Million INR | 79.58% |
| 2018 Q3 | 243.1 Million INR | -27.56% |
| 2018 Q2 | 335.6 Million INR | -24.62% |
| 2018 Q1 | 445.2 Million INR | 34.06% |
| 2018 FY | 1.16 Billion INR | -2.18% |
| 2018 Q4 | 144.94 Million INR | -40.37% |
| 2017 FY | 1.19 Billion INR | -11.21% |
| 2017 Q4 | 332.1 Million INR | 0.0% |
| 2016 Q4 | 329.2 Million INR | 0.0% |
| 2016 FY | 1.34 Billion INR | 6.78% |
| 2015 Q3 | 258.5 Million INR | -32.33% |
| 2015 Q2 | 382 Million INR | 9.33% |
| 2015 Q1 | 349.4 Million INR | 2.89% |
| 2015 FY | 1.26 Billion INR | -12.68% |
| 2015 Q4 | 277.1 Million INR | 7.2% |
| 2014 FY | 1.44 Billion INR | -6.04% |
| 2014 Q2 | 394.8 Million INR | 20.62% |
| 2014 Q3 | 381.8 Million INR | -3.29% |
| 2014 Q4 | 339.57 Million INR | -11.06% |
| 2014 Q1 | 327.3 Million INR | -7.01% |
| 2013 Q1 | 358.1 Million INR | -27.0% |
| 2013 Q4 | 351.97 Million INR | -0.88% |
| 2013 Q3 | 355.1 Million INR | -21.42% |
| 2013 Q2 | 451.9 Million INR | 26.19% |
| 2013 FY | 1.53 Billion INR | -14.29% |
| 2012 Q3 | 729.4 Million INR | 117.08% |
| 2012 Q4 | 490.55 Million INR | -32.75% |
| 2012 FY | 1.79 Billion INR | -87.78% |
| 2012 Q1 | 253.4 Million INR | -98.16% |
| 2012 Q2 | 336 Million INR | 32.6% |
| 2011 Q3 | 274.4 Million INR | 0.0% |
| 2011 FY | 14.66 Billion INR | 630.33% |
| 2011 Q4 | 13.73 Billion INR | 4905.89% |
| 2010 FY | 2 Billion INR | -82.36% |
| 2009 FY | 11.38 Billion INR | 1.98% |
| 2008 Q4 | 2.55 Billion INR | 0.0% |
| 2008 FY | 11.16 Billion INR | 8.71% |
| 2007 FY | 10.26 Billion INR | 42.22% |
| 2006 FY | 7.21 Billion INR | 12.99% |
| 2005 FY | 6.38 Billion INR | 21.81% |
| 2004 FY | 5.24 Billion INR | -5.75% |
| 2003 FY | 5.56 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Hester Biosciences Limited | 3.04 Billion INR | 48.289% |
| RPG Life Sciences Limited | 5.82 Billion INR | 72.943% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 85.021% |
| Ipca Laboratories Limited | 77.05 Billion INR | 97.956% |
| Aarti Drugs Limited | 25.28 Billion INR | 93.772% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 91.326% |
| Albert David Limited | 3.62 Billion INR | 56.551% |
| Alkem Laboratories Limited | 126.67 Billion INR | 98.757% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 97.423% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | -3.292% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 66.734% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -293.366% |
| Brooks Laboratories Limited | 794.86 Million INR | -98.129% |
| Eris Lifesciences Limited | 20.09 Billion INR | 92.162% |
| FDC Limited | 19.42 Billion INR | 91.895% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 93.102% |
| Gufic Biosciences Limited | 8.06 Billion INR | 80.477% |
| Hikal Limited | 17.84 Billion INR | 91.175% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 87.705% |
| Ind-Swift Limited | 5.02 Billion INR | 68.658% |
| Innova Captab Limited | 10.81 Billion INR | 85.436% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | 92.616% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | 24.541% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 97.65% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -2.016% |
| Laurus Labs Limited | 50.01 Billion INR | 96.851% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | 72.873% |
| Lupin Limited | 196.56 Billion INR | 99.199% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | 57.13% |
| Medico Remedies Limited | 1.44 Billion INR | -8.67% |
| Morepen Laboratories Limited | 17.01 Billion INR | 90.746% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 90.651% |
| Orchid Pharma Limited | 8.19 Billion INR | 80.78% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 86.321% |
| Sigachi Industries Limited | 3.98 Billion INR | 60.526% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 87.283% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.675% |
| Themis Medicare Limited | 3.81 Billion INR | 58.748% |
| Unichem Laboratories Limited | 16.57 Billion INR | 90.498% |
| Vaishali Pharma Limited | 862.79 Million INR | -82.529% |
| Venus Remedies Limited | 5.91 Billion INR | 73.373% |
| Wanbury Limited | 5.75 Billion INR | 72.642% |
| Windlas Biotech Limited | 6.3 Billion INR | 75.04% |
| ZIM Laboratories Limited | 3.67 Billion INR | 57.149% |
| Sakar Healthcare Limited | 1.54 Billion INR | -2.152% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 99.457% |
| Divi's Laboratories Limited | 78.45 Billion INR | 97.993% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 87.844% |
| Mankind Pharma Limited | 103.34 Billion INR | 98.476% |
| Sequent Scientific Limited | 13.69 Billion INR | 88.502% |
| Neuland Laboratories Limited | 15.58 Billion INR | 89.896% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | 95.432% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 98.667% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 99.172% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 62.613% |
| Wockhardt Limited | 27.89 Billion INR | 94.353% |
| Bal Pharma Limited | 3.39 Billion INR | 53.574% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 99.436% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 79.554% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -64.664% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | 90.608% |
| Shilpa Medicare Limited | 11.53 Billion INR | 86.343% |
| Valiant Laboratories Limited | 1.82 Billion INR | 13.497% |
| Ajanta Pharma Limited | 42.08 Billion INR | 96.258% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | 60.193% |
| Granules India Limited | 45.06 Billion INR | 96.505% |
| Medicamen Biotech Limited | 1.79 Billion INR | 12.17% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | 39.252% |
| Piramal Enterprises Limited | 60.33 Billion INR | 97.39% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 98.515% |
| NATCO Pharma Limited | 40.02 Billion INR | 96.065% |
| Suven Life Sciences Limited | 116.92 Million INR | -1246.846% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -212.338% |
| Strides Pharma Science Limited | 40.51 Billion INR | 96.113% |
| Indoco Remedies Limited | 18.17 Billion INR | 91.334% |
| Alpa Laboratories Limited | 1.08 Billion INR | -44.829% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -50.942% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -108.465% |